Background on Key Players and Relevance
The cannabis industry, primarily operating in Canada and the United States, experienced significant stock declines following U.S. President Donald Trump’s executive order to reclassify marijuana. This move, while not legalizing cannabis, modifies the regulatory framework, potentially easing access to capital, reducing tax burdens for cannabis businesses, and accelerating research and development.
Impact on Major Cannabis Companies
Key cannabis companies, especially those listed on the Toronto Stock Exchange, suffered substantial drops in their stock prices:
- Cresco Labs: Down 44.35% to C$1.63
- Trulieve Cannabis: Down 22.27% to C$11.90
- Green Thumb Industries: Down 15.31% to C$11.00
- Canopy Growth: Down 12.45% to C$2.32
Wall Street-listed cannabis companies also experienced single-digit declines:
- Tilray Brands: Down 4.19% to US$12.34
- Organigram Global: Down 3.79% to C$2.03
- Aurora Cannabis: Down 3.41% to C$5.38
- Cronos Group: Down 1.98%
- SNDL: Down 1.45%
Reasons Behind the Stock Declines
Frederico Gomes, an analyst at ATB Capital Markets, explained that some investors expected immediate and unilateral reclassification by President Trump. However, the executive order instructs the Attorney General to finalize the reclassification.
Art Hogan, Chief Market Strategist at B. Riley Wealth, noted that cannabis stocks remain highly speculative investments and “will likely continue to be so.”
Details of Trump’s Executive Order
The executive order instructs the U.S. Attorney General to reclassify cannabis from Schedule I narcotic to Schedule III drug, placing it in the same category as medications like Tylenol with codeine. Despite this, cannabis will remain illegal at the federal level.
The reclassification would allow for broader scientific research into its potential therapeutic benefits. Trump also ordered White House officials to collaborate with Congress to facilitate access for some Americans to cannabidiol (CBD).
Health authorities must develop “methods and models” to more accurately assess the real benefits and risks of CBD for health.
A high-ranking government official described the measure as a “common-sense decision that will help better understand and study both cannabis and CBD.”
Key Questions and Answers
- Q: What did Trump’s executive order do? A: It instructed the U.S. Attorney General to reclassify cannabis from Schedule I narcotic to Schedule III drug.
- Q: How will this reclassification affect the cannabis industry? A: It could ease access to capital, reduce tax burdens for cannabis businesses, and accelerate research and development.
- Q: Will cannabis be legal at the federal level after this reclassification? A: No, cannabis will remain illegal at the federal level despite the reclassification.
- Q: What are the implications for scientific research on cannabis? A: The reclassification allows for broader scientific research into its potential therapeutic benefits.
- Q: How will this impact access to cannabidiol (CBD) in the U.S.? A: White House officials will collaborate with Congress to facilitate access for some Americans to CBD.
